Download our whitepaper,

Rheumatoid Arthritis Clinical Trials:
Navigating Diagnosis, Endpoints,
and Protocol Enhancements

What's Inside:

  • Key FDA-Approved Pivotal Endpoints for Rheumatoid Arthritis Clinical Trials.
  • Optimizing Recruitment with Adaptive Trial Designs for Rheumatoid Arthritis.
  • Comprehensive Analysis of FDA-Approved Rheumatoid Arthritis Drugs.
  • How Diagnostic Criteria for Rheumatoid Arthritis Have Evolved and Impact Research.
  • Overcoming Common Pitfalls in Rheumatoid Arthritis Clinical Trials.
  • And additional insights to drive your trial’s success.

Access your complimentary whitepaper today:






    Rheumatoid Arthritis Clinical Trials

    Rheumatoid arthritis (RA) is a chronic autoimmune disorder that primarily affects the joints, causing inflammation, pain, and swelling. Over time, this inflammation can lead to joint damage and deformities, making daily activities challenging for those affected.

    Recent advances in understanding the immune pathways involved in rheumatoid arthritis have led to the development of more targeted therapies, aiming to reduce inflammation and slow disease progression. These therapies focus not only on symptom relief but also on addressing the underlying causes of joint damage and systemic inflammation.

    At iNGENū, our team of researchers and clinicians is dedicated to advancing rheumatoid arthritis research. By leveraging innovative trial designs and a patient-centered approach, we aim to accelerate the development of new treatments that have the potential to improve the quality of life for individuals living with rheumatoid arthritis.

    Up to

    50%

    of patients experience osteoporosis, as inflammation affects bone density

    With early treatment,

    30%

    of patients can achieve remission

    2.5x

    greater risk of developing rheumatoid arthritis for smokers

    Our clinical team has over

    120 years

    of combined clinical trial experience